Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
This study has been completed.
First Received: May 12, 2006   Last Updated: May 6, 2009   History of Changes
Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00326326
  Purpose

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes


Condition Intervention Phase
Dyslipidemia
 Drug: CP-778,875
 Phase II

MedlinePlus related topics: Cholesterol Diabetes
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • HDL-C Safety and Efficacy

Estimated Enrollment: 84
Study Start Date: July 2006
Study Completion Date: June 2007
  Eligibility

Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
  • Triglycerides between 150-500 mg/dL
  • Fasting Plasma Glucose 140-240 mg/dL

Exclusion Criteria:

  • Known cardiovascular, carotid, or peripheral vascular disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00326326

  Show 31 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site
Link to ClinicalStudyResults.org posting:  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: A5561005
Study First Received: May 12, 2006
Last Updated: May 6, 2009
ClinicalTrials.gov Identifier: NCT00326326     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
 Glucose Metabolism Disorders
Metabolic Disorder
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
 Glucose Metabolism Disorders
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on May 07, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services